Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard Post History

by PoorOpinion


T.TH

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RBC

I'm pretty cynical about biotech pipelines but based on experience of...

February 22, 2019

ATBPF

RE:RE:nice to see - recognition

You're continuous moaning is tedious. CyrolQue wrote: Great! Dilution is...

February 22, 2019

T.TH

RE:RE:RE:RE:RE:RE:RE:RE:RE:RBC

For me a yes/no answer to one very simple question would seriously reduce the...

February 22, 2019

T.TH

RE:RE:RE:RE:RE:Grinspoon is starting another study with Egrifta

They also did a number of studies on the 800 or so patients from the original...

February 21, 2019

T.TH

RE:RE:RE:RE:RE:Up

I like this review from 2018 https://www.ncbi.nlm.nih.gov/pmc/articles...

February 21, 2019

T.TH

RE:RE:RE:Up

One analyst did ask about how the NIH guidelines impacted the sales process...

February 21, 2019

T.TH

RE:RE:Up

If you're right that the market is reacting to the NASH info, that was my...

February 21, 2019

T.TH

RE:RE:400-450 Patients by end of April

I dont know if you are specifically right about that but your general...

February 21, 2019

T.TH

RE:RE:RE:RE:RE:RE:NASH results at the end of March early April

So early April hopefully (still Grinspoon has control over this). Coincides...

February 21, 2019

T.TH

RE:RE:NASH results at the end of March early April

Just to add to that.  They already have various scenario's in mind....

February 21, 2019

T.TH

RE:RE:RE:RE:RE:RE:RE:RE:ICPT data out this am

Dont know if anybody listened to the Intercept cc, there was a huge number of...

February 19, 2019

T.TH

RE:RE:RE:RE:RE:RE:ICPT data out this am

If they could get NASH data out around earnings this might end up being...

February 19, 2019

T.TH

RE:RE:RE:RE:ICPT data out this am

So what I'm reading is the result is less than stellar but it stands out...

February 19, 2019

ATBPF

RE:Citagenix alone brought in about 10M Candian last year.

Citigenix is still losing 0.5mil/quarter USA revenue was 625,000 this quarter...

February 17, 2019

T.TH

RE:RE:RE:RE:RE:RE:Sales Revenue (4147 TMB) January 2019

I had wondered whether the emphasis on the these higher expectations over the...

February 17, 2019

T.TH

RE:RE:Sales Revenue (4147 TMB) January 2019

I'd definitely agree with jfm that this is the rational way to use the...

February 17, 2019

T.TH

RE:RE:NASH data release expectations

This review talks about the two imaging techniques listed in the clinical...

February 15, 2019

T.TH

RE:NASH data release expectations

If this is the clinical trial https://clinicaltrials.gov/ct2/show...

February 15, 2019

T.WEED

RE:RE:RED FLAG

Lets be realistic - good,bad,meh whatever. These numbers are going to appear...

February 14, 2019

T.TH

Recent review of NASH in HIV

https://link.springer.com/article/10.1007/s40121-018-0229-7 Very recent...

February 14, 2019

Featured Company